Form 4: Vanda Pharmaceuticals CEO Increases Stake in Company
SEC Form 4 Filing
Mihael Hristos Polymeropoulos, President and CEO of Vanda Pharmaceuticals, recently purchased 10,000 shares of the company's common stock.
Summary
- On March 6, 2025, Mihael Hristos Polymeropoulos, the President and CEO of Vanda Pharmaceuticals, acquired 10,000 shares of Vanda Pharmaceuticals' common stock.
- The purchases were made in two transactions, each for 5,000 shares.
- The price per share was $5.02 for the first 5,000 shares and $5.01 for the second 5,000 shares.
- Following these transactions, Polymeropoulos directly owns 2,295,731 shares of Vanda Pharmaceuticals' common stock.
Sentiment
Score: 6
Explanation: The sentiment is neutral to slightly positive. The CEO's purchase suggests confidence, but it's a single event and doesn't provide a comprehensive view of the company's health.
Positives
- The CEO's purchase of shares could be interpreted as a positive signal, indicating confidence in the company's future prospects.
Industry Context
Insider buying is often seen as a positive sign, suggesting that a company's leadership believes the stock is undervalued. However, it's important to consider the overall context and not rely solely on insider transactions when making investment decisions.
Stakeholder Impact
- Shareholders may view the CEO's stock purchase as a positive signal.
Key Dates
| Date | Description |
|---|---|
| 03/06/2025 | Date of stock purchase transactions by Mihael Hristos Polymeropoulos |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.